Park Ha Biological Technology (BYAH) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
4 Jun, 2026Management team and governance
Principal executive offices are located in Wuxi, Jiangsu Province, China, with a U.S. agent for service in New York.
The CEO is Xiaoqiu Zhang, who also serves as a director; other key officers include the CFO (Xiaoyan Zhu), CTO (Xinyu Li), and additional directors.
Directors and officers are indemnified against losses except in cases of dishonesty, fraud, or willful neglect.
Offering details and pricing
The registration statement is for the issuance of securities from time to time after the effective date, under a shelf registration (Form F-3).
The offering may include senior and subordinated debt securities, warrants, rights, share purchase contracts, and units, with terms to be set by board resolution or supplemental indenture.
Securities may be issued in one or more series, with an unlimited aggregate principal amount authorized.
Underwriters and syndicate
Any underwriting agreement will provide for indemnification of the company and its officers and directors in certain cases.
Latest events from Park Ha Biological Technology
- Offering up to $300M in securities, the company targets skincare growth in China amid high regulatory risk.BYAH
Registration filing19 May 2026 - Offering up to $300 million in securities, the company targets growth in China's skincare market amid regulatory risks.BYAH
Registration filing16 Apr 2026 - FY2025 saw revenue growth but a large net loss due to share-based compensation, with strong gross margins.BYAH
Q4 20252 Mar 2026 - IPO raised $4.8M, shares listed as "PHH" on Nasdaq, with strong governance and incentive plans.BYAH
Registration Filing23 Jan 2026 - FY2024 revenue declined 3% to $2.38M, net income dropped 44%, and gross margin rose to 92%.BYAH
Q4 20247 Dec 2025 - Franchise skincare firm seeks $2.5M for store expansion, with high China regulatory and market risks.BYAH
Registration Filing7 Dec 2025 - High-margin skincare business with broad China presence and ongoing R&D-driven growth.BYAH
Corporate Presentation7 Dec 2025 - Franchise skincare firm seeks $3.5M via Nasdaq share/warrant offering amid regulatory and financial risks.BYAH
Registration Filing30 Nov 2025 - IPO targets $7.2M for China skincare expansion; CEO retains control; FY2023 revenue up, H1 2024 down.BYAH
Registration Filing29 Nov 2025